This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jaskowski, T. D.
Right arrow Articles by Hill, H. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jaskowski, T. D.
Right arrow Articles by Hill, H. R.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, June 2006, p. 655-660, Vol. 13, No. 6
1071-412X/06/$08.00+0     doi:10.1128/CVI.00034-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Analysis of Serum Antibodies in Patients Suspected of Having Inflammatory Bowel Disease

Troy D. Jaskowski,1* Christine M. Litwin,1,2 and Harry R. Hill1,2,3

Associated Regional and University Pathologists Institute for Clinical and Experimental Pathology,1 Departments of Pathology,2 Pediatrics and Medicine, University of Utah School of Medicine, Salt Lake City, Utah 841083

Received 27 January 2006/ Returned for modification 2 March 2006/ Accepted 23 March 2006

Inflammatory bowel disease (IBD) is the general term used for a heterogeneous group of intestinal disorders, including Crohn's disease (CD) and ulcerative colitis (UC). Serological markers such as anti-Saccharomyces cerevisiae antibodies (ASCA) and atypical perinuclear antineutrophilic cytoplasmic antibody (atypical pANCA) have proven useful in the diagnosis and differentiation of CD and UC. Immunoglobulin A (IgA) antibody directed against the outer membrane protein C (OmpC) of Escherichia coli is said by one group to have clinical utility in diagnosing IBD, specifically in ASCA-negative CD patients. Our objective in this study was to compare the results obtained from two separate laboratories offering similar IBD tests using sera from suspected IBD patients. One hundred ninety-seven sera received for IBD testing were included in the study. The agreement between the two laboratories was 93.4% for ASCA IgA, 90.9% for ASCA IgG, and 87.8% for atypical pANCA IgG. There were 25 sera with ASCA-negative/OmpC-positive results reported by one laboratory. Thirteen of these 25 (52.0%) ASCA-negative/OmpC-positive sera were also atypical pANCA positive (9 as determined by both laboratories, 3 by one, and 1 by the other). Atypical pANCA antibody is found primarily in IBD patients with UC and colon-limited CD (Crohn's colitis). We conclude that the ASCA and atypical pANCA assays showed good agreement between the two laboratories, but the data for ASCA-negative/OmpC-positive sera suggest that many (52.0%) of these patients were more likely to have had UC or Crohn's colitis based on the presence of an atypical pANCA.

* Corresponding author. Mailing address: ARUP Institute for Clinical and Experimental Pathology, 500 Chipeta Way, Salt Lake City, UT 84108. Phone: (801) 583-2787, ext. 2817. Fax: (801) 584-5109. E-mail: jaskowtd{at}aruplab.com.

Clinical and Vaccine Immunology, June 2006, p. 655-660, Vol. 13, No. 6
1071-412X/06/$08.00+0     doi:10.1128/CVI.00034-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»